Nerandomilast Clinical Trials (2026): 12 Studies for Healthy & Interstitial Lung Diseases
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
12 Nerandomilast clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 8 indications (including Healthy & Interstitial Lung Diseases) and 3,246 total planned enrollment. 5 Phase 3 Nerandomilast trials and 1 Phase 2 are listed. 7 Nerandomilast clinical trials are actively recruiting at 104 U.S. sites across 35 states. Most recent activity: NCT07366034 (Apr 2031).
Where to Participate: All Nerandomilast Trial Sites in the U.S. (104 sites across 35 states)
Every actively recruiting Nerandomilasttrial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AL | University of Alabama - Division of Pulmonary and Critical Care Medicine | Birmingham35294 | NCT06195072 | Map |
| AL | University of Alabama at Birmingham | Birmingham35233 | NCT06238622 | Map |
| AL | University of Alabama at Birmingham | Birmingham35233 | NCT06806592 | Map |
| AZ | Mayo Clinic-Arizona | Scottsdale85259 | NCT06806592 | Map |
| AZ | University of Arizona | Tucson85724 | NCT06238622 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06195072 | Map |
| CA | Cedars-Sinai Medical Center | Los Angeles90048 | NCT06238622 | Map |
| CA | Keck School of Medicine at USC Medical Center | Los Angeles90033 | NCT06195072 | Map |
| CA | University of California Los Angeles | Los Angeles90095 | NCT06238622 | Map |
| CA | University of Southern California | Los Angeles90033 | NCT06238622 | Map |
| CA | Stanford University Medical Center | Palo Alto94305 | NCT06195072 | Map |
| CA | University of California Davis | Sacramento95817 | NCT06238622 | Map |
| CA | Paradigm Clinical Research - San Diego | San Diego92108 | NCT06806592 | Map |
| CO | National Jewish Health | Denver80206 | NCT06238622 | Map |
| CO | National Jewish Health | Denver80206 | NCT06806592 | Map |
| CT | Yale University School of Medicine | New Haven06510 | NCT06238622 | Map |
| CT | Yale University School of Medicine | New Haven06510 | NCT06806592 | Map |
| DC | Georgetown University | Washington D.C.20007 | NCT06238622 | Map |
| DC | Georgetown University Medical Center - Department of Rheumatology | Washington D.C.20007 | NCT06195072 | Map |
| FL | University of Florida | Gainesville32610 | NCT06238622 | Map |
| FL | Clinical Research Specialists LLC - Kissimmee | Kissimmee34746 | NCT06238622 | Map |
| FL | Advanced Pulmonary Research Institute | Loxahatchee Groves33470 | NCT06238622 | Map |
| FL | Miami VA Healthcare System | Miami33125 | NCT06806592 | Map |
| GA | Emory University School of Medicine | Atlanta30322 | NCT06195072 | Map |
| GA | Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead | Atlanta30309 | NCT06238622 | Map |
| GA | Piedmont Physicians Pulmonary & Sleep Medicine of Buckhead | Atlanta30309 | NCT06806592 | Map |
| GA | The Emory Clinic | Atlanta30322 | NCT06238622 | Map |
| IL | Northwestern University | Chicago60611 | NCT06195072 | Map |
| IL | Northwestern University | Chicago60611 | NCT06806592 | Map |
| IL | The University of Chicago Medical Center | Chicago60637 | NCT06806592 | Map |
| IL | The University of Chicago Medical Center (UCMC) | Chicago60637 | NCT06195072 | Map |
| IL | Northshore University Health System | Evanston60201 | NCT06238622 | Map |
| IL | Northshore University Health System | Evanston60201 | NCT06806592 | Map |
| KS | University of Kansas Medical Center | Kansas City66160 | NCT06238622 | Map |
| KS | University of Kansas Medical Center | Kansas City66160 | NCT06806592 | Map |
| KS | University of Kansas School of Medicine | Kansas City66160 | NCT06195072 | Map |
| LA | Tulane Medical Center | New Orleans70112 | NCT06238622 | Map |
| MD | Johns Hopkins Hospital | Baltimore21224 | NCT06238622 | Map |
| MD | Johns Hopkins University School of Medicine | Baltimore21224 | NCT06195072 | Map |
| MA | Beth Israel Deaconess Medical Center | Boston02215 | NCT06238622 | Map |
| MA | Boston University (BU) | Boston02215 | NCT06195072 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT06238622 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT06806592 | Map |
| MA | Brigham and Women's Hospital | Boston02115 | NCT07201922 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06195072 | Map |
| MA | Massachusetts General Hospital | Boston02114 | NCT06238622 | Map |
| MA | St. Elizabeth's Medical Center | Boston02135 | NCT06238622 | Map |
| MI | University of Michigan | Ann Arbor48109-0370 | NCT06195072 | Map |
| MI | University of Michigan | Ann Arbor48109 | NCT06238622 | Map |
| MI | Corewell Health William Beaumont University Hospital | Royal Oak48073 | NCT06238622 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT06238622 | Map |
| MN | University of Minnesota | Minneapolis55455 | NCT06806592 | Map |
| MN | Mayo Clinic | Rochester55905 | NCT06195072 | Map |
| MN | Mayo Clinic, Rochester | Rochester55905 | NCT06238622 | Map |
| MN | Mayo Clinic, Rochester | Rochester55902 | NCT06806592 | Map |
| MO | The Lung Research Center, LLC | Chesterfield63017 | NCT06238622 | Map |
| NE | Creighton University | Omaha68124 | NCT06238622 | Map |
| NE | University of Nebraska Medical Center | Omaha68198 | NCT06238622 | Map |
| NE | University of Nebraska Medical Center | Omaha68198-1230 | NCT06806592 | Map |
| NV | Renown Regional Medical Center | Reno89502 | NCT06238622 | Map |
| NH | Dartmouth-Hitchcock Medical Center | Lebanon03756 | NCT06238622 | Map |
| NJ | Robert Wood Johnson Medical School | New Brunswick08901 | NCT06195072 | Map |
| NY | Northwell Health | Great Neck11021 | NCT06195072 | Map |
| NY | Northern Westchester Hospital | Mount Kisco10549 | NCT06238622 | Map |
| NY | Columbia University Medical Center | New York10032 | NCT06195072 | Map |
| NY | Columbia University Medical Center-New York Presbyterian Hospital | New York10032 | NCT06238622 | Map |
| NY | Hospital for Special Surgery | New York10021 | NCT06195072 | Map |
| NY | NewYork-Presbyterian/Weill Cornell Medical Center | New York10065 | NCT06238622 | Map |
| NY | NYU Langone Health | New York10017 | NCT06806592 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06195072 | Map |
| NC | Duke University Medical Center | Durham27710 | NCT06238622 | Map |
| NC | Onsite Clinical Solutions | Salisbury28144 | NCT06806592 | Map |
| NC | Southeastern Research Center-Winston Salem-69289 | Winston-Salem27103 | NCT06238622 | Map |
| NC | Southeastern Research Center-Winston Salem-69289 | Winston-Salem27103 | NCT06806592 | Map |
| OH | University of Cincinnati | Cincinnati45267 | NCT06238622 | Map |
| OH | Cleveland Clinic | Cleveland44195 | NCT06238622 | Map |
| OH | The Ohio State University Wexner Medical Center | Columbus43210 | NCT06238622 | Map |
| OR | Oregon Health & Science University (OHSU) | Portland97239 | NCT06195072 | Map |
| PA | Temple Lung Center | Philadelphia19140 | NCT06806592 | Map |
| PA | Temple University Hospital | Philadelphia19140 | NCT06238622 | Map |
| PA | Thomas Jefferson University Hospital | Philadelphia19107 | NCT06195072 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT06195072 | Map |
| PA | University of Pennsylvania | Philadelphia19104 | NCT06238622 | Map |
| PA | Allegheny General Hospital | Pittsburgh15212 | NCT06238622 | Map |
| PA | University of Pittsburgh Medical Center | Pittsburgh15213 | NCT06806592 | Map |
| RI | Infinity Medical Research, Inc. | East Providence02914 | NCT06238622 | Map |
| SC | Lowcountry Lung and Critical Care | Charleston29406 | NCT06238622 | Map |
| SC | Medical University of South Carolina (MUSC) | Charleston29404 | NCT06195072 | Map |
| TN | Clinical Trials Center of Middle Tennessee, LLC | Franklin37067 | NCT06238622 | Map |
| TN | Vanderbilt University Medical Center | Nashville37204 | NCT06238622 | Map |
| TX | Baylor University Medical Center | Dallas75246 | NCT06238622 | Map |
| TX | The University of Texas Health Science Center at Houston | Houston77030 | NCT06806592 | Map |
| TX | University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics | Houston77030 | NCT06195072 | Map |
| TX | University of Texas Health Science Center at San Antonio | San Antonio78229 | NCT06806592 | Map |
| TX | UT Health San Antonio | San Antonio78229 | NCT06238622 | Map |
| UT | Intermountain Medical Center-Murray-69497 | Murray84107 | NCT06238622 | Map |
| UT | University of Utah Health Sciences Center | Salt Lake City84108 | NCT06238622 | Map |
| VT | University of Vermont | Burlington05401 | NCT06238622 | Map |
| VA | Inova Fairfax Hospital | Falls Church22042 | NCT06238622 | Map |
| WA | Virginia Mason Medical Center | Seattle98101 | NCT06238622 | Map |
| WV | Rheumatology and Pulmonary Clinic | Beckley25801 | NCT06806592 | Map |
| WI | University of Wisconsin | Madison53792 | NCT06238622 | Map |
| WI | University of Wisconsin | Madison53792 | NCT06806592 | Map |
| WI | Froedtert Hospital and the Medical College of Wisconsin | Milwaukee53226 | NCT06195072 | Map |
Nerandomilast clinical trials at a glance: phase × recruitment status
| Phase | recruiting | completed | not yet recruiting | Total |
|---|---|---|---|---|
| P1 | 5 | 5 | ||
| P2 | 1 | 1 | ||
| P2/P3 | 1 | 1 | ||
| P3 | 3 | 2 | 5 |
Recruiting Nerandomilast clinical trials (7)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07366034 | A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) | P3 | Fibrosing Interstitial Lung Disease | 35 | Jul 2026 |
| NCT07497087 | VERANDA™-SScA Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | P3 | Systemic Sclerosis | 448 | Jun 2026 |
| NCT07201922 | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis | P3 | Familial Pulmonary Fibrosis | 80 | Feb 2026 |
| NCT07321860 | This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling | P2/P3 | ALS (Amyotrophic Lateral Sclerosis) | 60 | Jun 2026 |
| NCT06806592 | A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases | P3 | Interstitial Lung Diseases | 400 | Sep 2025 |
| NCT06238622 | FIBRONEER™-ONA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | P3 | Idiopathic Pulmonary Fibrosis | 1,700 | May 2024 |
| NCT06195072 | CONQUESTPlatform Clinical Study for Conquering Scleroderma | P2 | Interstitial Lung Disease Due to Systemic Disease | 400 | Apr 2024 |
Nerandomilast clinical trials by indication
Healthy (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07081932 | — | P1 | completed | A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood |
| NCT07100964 | — | P1 | completed | A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood |
| NCT06624072 | — | P1 | completed | A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food |
| NCT06393127 | — | P1 | completed | A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body |
| NCT06139302 | BI 1015550 | P1 | completed | A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men |
Fibrosing Interstitial Lung Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07366034 | — | P3 | not yet recruiting | A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) |
ALS (Amyotrophic Lateral Sclerosis) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07321860 | — | P2/P3 | not yet recruiting | This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling |
Systemic Sclerosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07497087 | VERANDA™-SSc | P3 | not yet recruiting | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis |
Familial Pulmonary Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07201922 | — | P3 | recruiting | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis |
Interstitial Lung Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06806592 | — | P3 | recruiting | A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases |
Idiopathic Pulmonary Fibrosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06238622 | FIBRONEER™-ON | P3 | recruiting | A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast |
Interstitial Lung Disease Due to Systemic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06195072 | CONQUEST | P2 | recruiting | Platform Clinical Study for Conquering Scleroderma |
Nerandomilast pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| VERANDA™-SSc | NCT07497087 | P3 | not yet recruiting | Systemic Sclerosis | 448 | — |
| FIBRONEER™-ON | NCT06238622 | P3 | recruiting | Idiopathic Pulmonary Fibrosis | 1,700 | — |
| CONQUEST | NCT06195072 | P2 | recruiting | Interstitial Lung Disease Due to Systemic Disease | 400 | — |
All Nerandomilast trials (12)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07366034 | A Study to Find Out How Nerandomilast is Tolerated, Handled by the Body, and if it Helps Children and Adolescents With Interstitial Lung Disease (FIBRONEER-chILD) | P3 | not yet recruiting | 35 | Boehringer Ingelheim | Jul 2026 | |
| NCT07497087 | VERANDA™-SSc | A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis | P3 | not yet recruiting | 448 | Boehringer Ingelheim | Jun 2026 |
| NCT07201922 | A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis | P3 | recruiting | 80 | Boehringer Ingelheim | Feb 2026 | |
| NCT07321860 | This Study Evaluates the Safety, Target Engagement, and Preliminary Efficacy of Galunisertib (TGF-βR1/ALK5 Inhibitor)Combined With Nerandomilast (PDE4 Inhibitor) in GREM2-positive ALS, a Biomarker-defined Subgroup Hypothesized to Reflect Heightened TGF-β/SMAD-driven Astrocytic and Fibrotic Signaling | P2/P3 | not yet recruiting | 60 | Gipfel Life Sciences GmbH | Jun 2026 | |
| NCT06806592 | A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases | P3 | recruiting | 400 | Boehringer Ingelheim | Sep 2025 | |
| NCT06238622 | FIBRONEER™-ON | A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | P3 | recruiting | 1,700 | Boehringer Ingelheim | May 2024 |
| NCT06195072 | CONQUEST | Platform Clinical Study for Conquering Scleroderma | P2 | recruiting | 400 | Scleroderma Research Foundation, Inc. | Apr 2024 |
| NCT07081932 | A Study in Healthy Men to Test How Bosentan Influences the Amount of Nerandomilast in the Blood | P1 | completed | 16 | Boehringer Ingelheim | Aug 2025 | |
| NCT07100964 | A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Nerandomilast in the Blood | P1 | completed | 16 | Boehringer Ingelheim | Aug 2025 | |
| NCT06624072 | A Study in Healthy People to Compare 2 Different Formulations of Nerandomilast Tablets When Taken With or Without Food | P1 | completed | 15 | Boehringer Ingelheim | Oct 2024 | |
| NCT06393127 | A Study in Healthy People to Compare How 2 Different High Dose Formulations of BI 1015550 Are Taken up in the Body | P1 | completed | 64 | Boehringer Ingelheim | Jun 2024 | |
| NCT06139302 | BI 1015550 | A Study to Test How Different Doses of Nerandomilast (BI 1015550) Are Taken up in the Body of Healthy Japanese Men | P1 | completed | 12 | Boehringer Ingelheim | Dec 2023 |
Nerandomilast clinical trials: frequently asked questions
- How many Nerandomilast clinical trials are there?
- 12 Nerandomilast clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 4 are actively recruiting participants. 5 are marked completed.
- Are Nerandomilast clinical trials recruiting in 2026?
- Yes — 4 Nerandomilast trials are actively recruiting in 2026, with 104 U.S. sites across 35 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is Nerandomilast being studied for?
- Nerandomilast is being studied for Healthy, Interstitial Lung Diseases, Fibrosing Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Interstitial Lung Abnormalities and 7 more. The trials are grouped by indication on this page.
- What phase is Nerandomilast in?
- Nerandomilast clinical trials span 5 Phase 3, 1 Phase 2, 5 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Nerandomilast clinical trials?
- The lead sponsor across the most Nerandomilast trials is Boehringer Ingelheim, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Nerandomilastas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: